ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - crizotinib - קפסולות - crizotinib 200 mg - crizotinib - crizotinib - xalkori is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - crizotinib - קפסולות - crizotinib 250 mg - crizotinib - crizotinib - xalkori is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - crizotinib - קפסולות - crizotinib 250 mg - crizotinib - crizotinib - xalkori is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive.

ישראל - עברית - Ministry of Health

novartis israel ltd - topotecan as hydrochloride - קפסולות ג'לטין קשיחות - topotecan as hydrochloride 0.25 mg - topotecan - topotecan - indicated for the treatment of patients with relapsed small cell lung cancer (sclc) for whom re-treatment with the first-line regimen is not considered appropriate.

ישראל - עברית - Ministry of Health

novartis israel ltd - topotecan as hydrochloride - קפסולות ג'לטין קשיחות - topotecan as hydrochloride 1 mg - topotecan - topotecan - indicated for the treatment of patients with relapsed small cell lung cancer (sclc) for whom re-treatment with the first-line regimen is not considered appropriate.

ישראל - עברית - Ministry of Health

astrazeneca (israel) ltd - gefitinib - טבליות מצופות פילם - gefitinib 250 mg - gefitinib - gefitinib - iressa is indicated as monotherapy for the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies who are benefiting or have benefited from iressa. results from two large controlled randomized trials in first-line treatment of non-small cell lung cancer showed no benefit from adding iressa to doublet platinum-based chemotherapy.iressa is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating mutations of egfr-tk.

ישראל - עברית - Ministry of Health

eisai israel ltd., israel - eribulin as mesilate - תמיסה להזרקה - eribulin as mesilate 0.44 mg/ml - eribulin - eribulin - halaven monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease. prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments.

ישראל - עברית - Ministry of Health

eisai israel ltd., israel - eribulin as mesilate - תמיסה להזרקה - eribulin as mesilate 0.44 mg/ml - eribulin - eribulin - halaven monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease. prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments.

ישראל - עברית - Ministry of Health

inovamed ltd - bicalutamide - טבליות מצופות פילם - bicalutamide 150 mg - bicalutamide - bicalutamide - in patients with locally advanced prostate cancer (t3 - t4 any n m0 t1 -t2 n+ m0), bicalutamide 150 mg is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. the management of patients with locally advanced non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable

ישראל - עברית - Ministry of Health

abic marketing ltd, israel - fentanyl as citrate - טבליות דחוסות על מקל - fentanyl as citrate 200 mcg/dose - fentanyl - fentanyl - actiq is indicated only for the management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.